Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/31/2013US8618096 Prodrug compositions and methods for using the same in treating cancer and malaria
12/31/2013US8618095 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
12/31/2013US8618094 Fused substituted aminopyrrolidine derivative
12/31/2013US8618093 Hypotensive lipid and timolol compositions and methods of using same
12/31/2013US8618092 Tricyclic oxazolidinone antibiotic compounds
12/31/2013US8618091 Composition and method for treatment of MRSA
12/31/2013US8618090 Inhibitors of the plasmodial surface anion channel as antimalarials
12/31/2013US8618089 Substituted porphyrins
12/31/2013US8618088 Methods of inhibiting choroidal neovascularization
12/31/2013US8618087 Solid ganaxolone formulations and methods for the making and use thereof
12/31/2013US8618086 Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
12/31/2013US8618085 Therapeutic formulations of desoxyepothilones
12/31/2013US8618084 Aldosterone induced vascular elastin production
12/31/2013US8618083 Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
12/31/2013US8618082 Lupeol anti-tumor agent and uses thereof
12/31/2013US8618081 Compositions, gels and foams with rheology modulators and uses thereof
12/31/2013US8618080 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
12/31/2013US8618079 Imidazo[1,2-a] pyridinyl bisphosphonates
12/31/2013US8618078 Foods and drinks having health benefits and method for adding health benefits to foods and drinks
12/31/2013US8618077 Compositions and methods for treating fragile X premutation RVGG repeats-mediated toxicity
12/31/2013US8618076 Nucleoside phosphoramidates
12/31/2013US8618075 Certain compounds, compositions and methods
12/31/2013US8618074 GPCR enhanced neuroprotection to treat brain injury
12/31/2013US8618072 Composition comprising expression or activity inhibitors of ninjurin1 for the prevention and treatment of inflammatory disease
12/31/2013US8618069 Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA
12/31/2013US8618068 Methods and low dose regimens for treating red blood cell disorders
12/31/2013US8618067 L-sugar colon cleansing agent and uses thereof
12/31/2013US8618066 Coating compositions having peptidic antimicrobial additives and antimicrobial additives of other configurations
12/31/2013US8618045 Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
12/31/2013US8617840 Lysis/resealing process and device for incorporating an active ingredient, in particular asparaginase or inositol hexaphosphate, in erythrocytes
12/31/2013US8617822 Method of inhibiting binding or activity of MIF by administering a MIF antagonist
12/31/2013US8617614 Sustained release preparation for tissue regeneration therapy
12/31/2013US8617613 Polymer-based sustained release device
12/31/2013US8617610 Compositions and methods for increasing the stability of food product additives
12/31/2013US8617608 Drug loaded polymeric nanoparticles and methods of making and using same
12/31/2013US8617607 Sustained release formulations of psychoactive drugs
12/31/2013US8617606 Hydrogel suspension and manufacturing process thereof
12/31/2013US8617599 Modified release compositions comprising tacrolimus
12/31/2013US8617598 Pharmaceutical compositions comprising colloidal silicon dioxide
12/31/2013US8617597 Pharmaceutical composition containing a tetrahydrofolic acid
12/31/2013US8617595 Galenic formulations of organic compounds
12/31/2013US8617594 Stable pharmaceutical composition and methods of using same
12/31/2013US8617593 Stable pharmaceutical composition and methods of using same
12/31/2013US8617591 Transdermal delivery system for the administration of rotigotine
12/31/2013US8617587 Tasted masked veterinary solid compositions
12/31/2013US8617582 Spot-on pesticide composition
12/31/2013US8617578 Compositions containing topical-active agents and pentyleneglycol
12/31/2013US8617541 Solubilized CoQ-10
12/31/2013US8617540 Combinational chemotherapy treatment
12/31/2013US8617539 Method of administration of platelet-rich plasma to treat an acute cardiac dysfunction
12/31/2013US8617534 Compositions and method for manipulating PIM-1 activity in circulatory system cells
12/31/2013US8617530 Polymer conjugates of opioid antagonists
12/31/2013US8617529 Use of organomodified siloxane block copolymers as care active ingredient for the care of human or animal body parts
12/31/2013US8617211 Spine distraction implant and method
12/31/2013CA2775266C Anti-cancer tamoxifen-melatonin hybrid ligand
12/31/2013CA2755268C Erbb inhibitors
12/31/2013CA2742833C Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
12/31/2013CA2742680C Pharmaceutical compositions for release control of methylphenidate
12/31/2013CA2739131C Antibiotic coating containing at least one humectant
12/31/2013CA2733795C Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
12/31/2013CA2707174C Benzomorphan compounds
12/31/2013CA2705318C Inhibitors of human immunodeficiency virus replication
12/31/2013CA2666246C Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
12/31/2013CA2651232C Combination of alovudine and zidovudine in a molar ratio of 1:100 to 1:350
12/31/2013CA2647116C Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as gaba receptor ligands
12/31/2013CA2645756C Malonamide derivatives as gamma secretase inhibitors
12/31/2013CA2644661C Prodrugs of benzoquinolizine-2-carboxylic acid
12/31/2013CA2636960C Pharmaceutical composition comprising a specific inhibitor of hedgehog/smoothened signaling and a corticosteroid
12/31/2013CA2630562C Tricyclic compounds useful as inhibitors of kinases
12/31/2013CA2629814C Bisamide inhibitors of hedgehog signaling
12/31/2013CA2629018C Aza-substituted spiro derivative
12/31/2013CA2625042C Iontophoretic preparation for treatment of breast cancer and/or mastitis
12/31/2013CA2619153C Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
12/31/2013CA2614846C Acne treatment
12/31/2013CA2613192C Histamine h3 receptor agents, preparation and therapeutic uses
12/31/2013CA2609347C Use of chalcones for the treatment of viral disorders
12/31/2013CA2608788C Spot-on formulations for combating parasites
12/31/2013CA2608378C New fluorene derivatives, compositions containing the same and use thereof
12/31/2013CA2608201C Heterocyclic inhibitors of mek and methods of use thereof
12/31/2013CA2604774C Method for improving the fertility of animals
12/31/2013CA2602965C Tricyclic spiro derivatives as crth2 modulators
12/31/2013CA2599974C Pyridine-2-carboxamide derivatives as mglur5 antagonists
12/31/2013CA2592978C Topical stabilized prostaglandin e compound dosage forms
12/31/2013CA2587489C Mediators of hedgehog signaling pathways, compositions and uses related thereto
12/31/2013CA2586195C Treatment of acne using derivatives of 5-aminolevulinic acid
12/31/2013CA2584485C Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
12/31/2013CA2569468C Ophthalmic formulations including selective alpha 1 antagonists
12/31/2013CA2567289C Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
12/31/2013CA2563496C Nicotine transdermal preparation and production method thereof
12/31/2013CA2554728C Production method of nicotine transdermal preparation
12/31/2013CA2552565C Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics
12/31/2013CA2548454C Medicament comprising recombinant antibody against chemokine receptor ccr4
12/31/2013CA2544678C Modulators of cellular adhesion
12/31/2013CA2542269C Fusion molecules comprising antigens and mhc i or ii cytoplasmic domains
12/31/2013CA2527145C Use of iron for treating attention deficit hyperactivity disorder in children
12/31/2013CA2525111C Drug formulations having reduced abuse potential
12/31/2013CA2523868C Combinations comprising a protein tyrosine kinase receptor antagonist and a chemotherapeutic or naturally occurring, semi-synthetic of synthetic therapeutic agent for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
12/31/2013CA2505088C Water soluble monomers and polymers for protecting subtrates from ultraviolet light
12/31/2013CA2485847C Glucan-based vaccines
12/31/2013CA2467908C Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages
1 ... 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 ... 7860